Cover Image

Update breast cancer 2018 (Part 4): genomics, individualized medicine and immune therapies - in the middle of a new era : treatment strategies for advanced breast cancer = Update Mammakarzinom 2018 (Part 4) : Genomforschung, individualisierte Medizin und Immuntherapien - mitten in einer neuen Ära : Therapie des fortgeschrittenen Mammakarzinoms

New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class...

Full description

Saved in:
Bibliographic Details
Main Authors: Müller, Volkmar (Author) , Schütz, Florian (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Geburtshilfe und Frauenheilkunde
Year: 2018, Volume: 78, Issue: 11, Pages: 1119-1128
ISSN:1438-8804
DOI:10.1055/a-0715-2899
Online Access:Verlag, Pay-per-use, Volltext: https://doi.org/10.1055/a-0715-2899
Verlag, Pay-per-use, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0715-2899
Get full text
Author Notes:Authors: Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Andreas D. Hartkopf, Naiba Nabieva, Florin-Andrei Taran, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Manfred Welslau, Erik Belleville, Sara Y. Brucker, Florian Schütz, Peter A. Fasching, Tanja N. Fehm, Hans-Christian Kolberg, Andreas Schneeweiss, Friedrich Overkamp
Description
Summary:New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments.
Item Description:Gesehen am 20.05.2019
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-0715-2899

Similar Items